Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BEAM Beam Therapeutics, Inc.

未开盘 08-12 16:00:00 EDT

26.71

-0.14

-0.52%

盘后26.82

+0.11+0.41%

19:53 EDT

最高27.31	最低26.62	成交量155.41万
今开27.00	昨收26.85	日振幅2.57%
总市值27.59亿	流通市值23.67亿	总股本1.03亿
成交额4,170万	换手率1.75%	流通股本8,861万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BEAM","market":"US","secType":"STK","nameCN":"Beam Therapeutics, Inc.","latestPrice":26.71,"timestamp":1786564800000,"preClose":26.85,"halted":0,"volume":1554142,"hourTrading":{"tag":"盘后","latestPrice":26.82,"preClose":26.71,"latestTime":"19:53 EDT","volume":320783,"amount":8568509.5977,"timestamp":1786578838342,"change":0.11,"changeRate":0.004118,"amplitude":0.009996},"delay":0,"changeRate":-0.00521415270018624,"floatShares":88612200,"shares":103287665,"eps":-0.837623,"marketStatus":"未开盘","change":-0.14,"latestTime":"08-12 16:00:00 EDT","open":27,"high":27.31,"low":26.62,"amount":41701347.367663994,"amplitude":0.025698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.837623,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786608000000},"marketStatusCode":0,"adr":0,"listingDate":1580965200000,"exchange":"NASDAQ","adjPreClose":26.85,"preHourTrading":{"tag":"盘前","latestPrice":27.07,"preClose":26.85,"latestTime":"09:29 EDT","volume":8199,"amount":224873.67783600002,"timestamp":1786541399999,"change":0.22,"changeRate":0.008194,"amplitude":0.033799},"postHourTrading":{"tag":"盘后","latestPrice":26.82,"preClose":26.71,"latestTime":"19:53 EDT","volume":320783,"amount":8568509.5977,"timestamp":1786578838342,"change":0.11,"changeRate":0.004118,"amplitude":0.009996},"volumeRatio":1.089419,"impliedVol":0.3918,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/BEAM","defaultTab":"news","newsList":[{"id":"1159265220","title":"Beam Therapeutics公布2026年第二季度财务业绩，并宣布在α-1抗胰蛋白酶缺乏症（AATD）领域Beam-302试验全球关键队列中首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1159265220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159265220?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:01","pubTimestamp":1785841273,"startTime":"0","endTime":"0","summary":"Beam Therapeutics（纳斯达克股票代码：BEAM）今日披露其2026年第二季度的财务表现，同时对外宣布，其针对α-1抗胰蛋白酶缺乏症（AATD）的研究性疗法Beam-302，已在全球关键性临床试验队列中完成首例患者给药。这一里程碑事件，标志着该候选药物在开发进程中迈出了至关重要的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4505","BK4588","BK4585","LU1861559042.SGD","BEAM","BK4139","BK4556","LU1861558580.USD","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651443872","title":"木头姐日内调仓分化 持续加码航天军工 减持农业基因标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651443872","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651443872?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:57","pubTimestamp":1784195848,"startTime":"0","endTime":"0","summary":"当日资金投入力度最大的标的为太空探索技术公司 ，多只 ARK 系 ETF 合计斥资 1670 万美元，买入 122807 股，对应成交均价约 135.99 美元，机构持续加大航天赛道配置比重。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SARK","HWAY","DE","SPCH","DFII","BCCC","IDNA","BTFX","FTAG","KTUP","SPAL","KTOS","161024","HODL","MADE","BITB","ARKW","CBXJ","SPCF","TXG","TWST","LOFF","CBTY","BTCL","ARKK","ARKX","ARKG","ARKQ","ARKF","SNK","VEGI","SHLD","KROP","BTRN","SPCU","QBF","BITU","SPCG","BEAM","CBXA","GNOM","ARKB","BETH","FMED","WDNA","BFAP","159041","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819136","title":"基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819136","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645819136?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:21","pubTimestamp":1782310862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美股基因编辑概念普升，截至发稿，安捷伦科技 (A) 涨 4.21%，Beam Therapeutics (BEAM) 涨 3.55%，Intellia Therapeutics (NTLA) 涨 2.95%，Editas Medicine (EDIT) 涨 2.17%，福泰制药 (VRTX) 涨 1.28%。消息面上，建银国际新近研究认为，美国FDA近期发布了基因编辑疗法审评新规，允许药企在提供充分科学可比性论证的前提下，引用“先验知识”或既往成熟研究数据以加速研发，此举这标志着基因编辑疗法审评思路的重要转变，直接利好拥有相关技术平台的企业。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301875","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00BJT1NW94.SGD","BK4505","LU1674673691.USD","IE00BN0W2V16.EUR","LU0432979614.USD","LU2462157665.USD","A","BK4139","LU0079474960.USD","IE00B19Z9Z06.USD","BK4611","LU1861559042.SGD","LU2089279066.USD","LABU","VRTX","BK4567","BK4588","NTLA","LU2236285917.USD","LU2413666699.HKD","LU1674673428.USD","SGXZ57979304.SGD","LU1035775433.USD","LU0889565916.HKD","BK4533","BK4121","LU2324357040.USD","LU0234570918.USD","LU0256863811.USD","SG9999013999.USD","LU2362540622.SGD","LU0058720904.USD","LU0417517546.SGD","LU2092937221.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","EDIT","IE00BN0W2W23.USD","LU2362541273.HKD","LU1861558580.USD","SG9999001176.SGD","IE00B894F039.SGD","BEAM","LU2229751404.USD","IE00BZ9MQY76.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","LU2041044095.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168068951","title":"Beam Therapeutics宣布其用于治疗苯丙酮尿症的在研新药Beam-304获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1168068951","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168068951?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:02","pubTimestamp":1781780553,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. 宣布，其用于治疗苯丙酮尿症的在研新药Beam-304，其新药临床试验申请已获得美国食品和药物管理局的许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4588","BK4611","BK4585","BK4535","BK4505","LU1861558580.USD","BK4556","BK4139","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116095845","title":"Beam Therapeutics股价盘前飙升14%，基因编辑药物在罕见肺肝疾病试验中展现积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1116095845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116095845?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:19","pubTimestamp":1774437552,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. (BEAM) 股价在盘前交易中大幅上涨14%，此前该公司宣布其研发的基因编辑药物在一项针对罕见肺肝疾病的临床试验中取得了令人鼓舞的结果。\n这一积极进展显著提振了投资者信心，推动公司股价在开盘前出现强劲上扬。试验数据的披露为Beam Therapeutics在基因治疗领域的技术实力提供了有力证明，同时也为相关罕见疾病患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4585","BK4556","BK4535","BK4588","BK4505","LU1861558580.USD","LU1861559042.SGD","BK4139","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118560812","title":"Beam Therapeutics公司：60毫克剂量被确定为最佳生物剂量，单剂量队列展现优异安全性与疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118560812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118560812?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:04","pubTimestamp":1774436652,"startTime":"0","endTime":"0","summary":"Beam Therapeutics公司宣布，基于单剂量队列中展现出的卓越安全性及疗效数据，60毫克剂量已被选定为最佳生物剂量。这一决定凸显了该剂量在治疗窗口中的优势地位，为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4505","BK4588","BK4556","LU1861558580.USD","BK4139","LU1861559042.SGD","BEAM","BK4611","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125593240","title":"Beam Therapeutics公布BEAM-302治疗α-1抗胰蛋白酶缺乏症1/2期试验最新积极数据 支持推进关键性开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125593240?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:03","pubTimestamp":1774436620,"startTime":"0","endTime":"0","summary":"Beam Therapeutics近日公布了其在研疗法BEAM-302针对α-1抗胰蛋白酶缺乏症（AATD）的1/2期临床试验最新数据。这些积极结果有力支持该疗法向关键性临床开发阶段推进。试验数据显示，BEAM-302在安全性和有效性方面均表现出令人鼓舞的潜力，为后续研发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4535","LU1861558580.USD","BK4585","LU1861559042.SGD","BK4611","BK4139","BEAM","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172694466","title":"Beam Therapeutics：经BEAM-302 60毫克治疗后，校正型M-AAT占总AAT的94%，同时突变型Z-AAT降低84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172694466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172694466?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:03","pubTimestamp":1774436593,"startTime":"0","endTime":"0","summary":"在Beam Therapeutics公司BEAM-302 60毫克治疗方案下，研究数据显示校正型M-AAT占全部AAT的比例高达94%。与此同时，突变型Z-AAT水平出现显著下降，降幅达到84%。这一结果凸显了该疗法在精准编辑方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1861559042.SGD","BK4556","LU1861558580.USD","BK4139","BK4585","BK4611","BK4505","BEAM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140891451","title":"Beam Therapeutics Inc.与Bio Palette共同终止2019年3月27日授权协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1140891451","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140891451?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:54","pubTimestamp":1772747674,"startTime":"0","endTime":"0","summary":"根据3月2日提交至美国证券交易委员会（SEC）的文件显示，Beam Therapeutics Inc.已与Bio Palette公司共同决定终止双方于2019年3月27日签订的授权协议。该协议的终止经双方协商一致，具体条款及后续安排未在申报文件中详细披露。此次变动标志着两家公司在基因编辑疗法领域的合作正式画上句号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","LU1861558580.USD","BEAM","BK4611","BK4505","BK4588","BK4585","BK4556","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108440596","title":"Beam Therapeutics公布2025年第四季度及全年财报，并宣布针对苯丙酮尿症（PKU）的新型肝脏靶向基因治疗项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1108440596","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108440596?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:03","pubTimestamp":1771934622,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc.（纳斯达克代码：BEAM）近日披露了2025年第四季度及全年财务业绩，同时正式启动针对苯丙酮尿症（PKU）的肝脏靶向基因治疗新项目。此次公布的财务数据展现了公司在基因编辑领域的持续投入与战略布局，而新项目的推出进一步拓展了其精准基因药物在遗传性疾病治疗中的应用边界。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4535","BK4588","BK4505","BK4139","LU1861559042.SGD","LU1861558580.USD","BEAM","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613293073","title":"华尔街顶级分析师最新评级：沃尔玛遭下调、Etsy获上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2613293073","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613293073?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:57","pubTimestamp":1771603020,"startTime":"0","endTime":"0","summary":"巴克莱将 Etsy 从持股观望上调至增持，目标价从 62 美元上调至 72 美元。该行认为，Etsy 出售 Depop、核心业务在多年下滑后趋于平稳，是公司的转折点。Argus将 Deckers Outdoor 从持有上调至买入，理由是管理层上调业绩指引，且预测更 “可靠”。第四季度水杯业务表现改善，有助于提振销售增长，缓解股价压力。该行认为，佐治亚州公共事业委员会选举带来的扰动被市场过度放大。富国银行也同步上调了该股评级。预计一季度末 BEAM-302 数据将成为股价催化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnnwya2609740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["DECK","LU1674673428.USD","LU0310799852.SGD","LU1585245621.USD","LU2125154935.USD","LU1064131342.USD","LU0211327993.USD","ETSY","BK4155","LU1066051498.USD","LU2097829019.USD","LU2361044949.HKD","LU0417517546.SGD","LAD","LU0661504455.SGD","RS","BK4597","LU0265550359.USD","LU0949170772.SGD","LU2360032135.SGD","LU0640476718.USD","WMT","BK4532","LU0957791311.USD","LU2430703251.USD","WMTI","LU2264538146.SGD","LU0096362180.USD","GB00BDT5M118.USD","BK4534","LU1430594728.SGD","LU0289960550.SGD","LU0314104364.USD","LU2505996509.AUD","BEAM","LU0256863811.USD","LU0061474960.USD","TNDM","BK4550","LU1066051811.HKD","BK4533","LU2361044865.SGD","LU1988902786.USD","LU2746668974.SGD","LU1116320901.HKD","LU1066051225.USD","LU2125154778.USD","SO","LU0353189763.USD","LU1280957306.USD","LU0265550946.USD","SYK","LU2471134952.CNY","LU1069347547.HKD","LU0553294199.USD","LU1267930490.SGD","LU2505996681.GBP","ZBH","LU1003077747.HKD","LU2471134879.HKD","LU0353189680.USD","IE0034235188.USD","LU1366192091.USD","LU0738911758.USD","LU2471134796.USD","BK4588","BK4596","LU2471134523.USD","MOH","LU2461242641.AUD","LU2592432038.USD","YETI","LU1035773651.USD","BWA","LU2430703178.SGD","BK4585","LU2087625088.SGD","LU2750360997.AUD","LU0149725797.USD","LU0175139822.USD","LU0256863902.USD","LU2750360641.GBP","LU0211328371.USD","LU1116320737.USD","LU2746668461.USD","LU2361045086.USD","BK4581","LU0545039389.USD","LU1674673691.USD","LU1066053197.SGD","LU0238689110.USD","IE000M9KFDE8.USD","GE","BK4504","LU1778281490.HKD","LU1814569148.SGD","AFRM","LU1815333072.USD","LU2430703095.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2518220291","title":"Beam Therapeutics Inc.盘中异动 大幅下跌5.20%报27.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220291?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:03","pubTimestamp":1741615383,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时03分，Beam Therapeutics Inc.股票出现异动，股价急速下跌5.20%。截至发稿，该股报27.00美元/股，成交量237.165万股，换手率2.83%，振幅3.72%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022030396403e21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022030396403e21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","LENZ","BK4505","BEAM","BK4611","BK4139","BK4585","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517200169","title":"Beam Therapeutics Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517200169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517200169?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:32","pubTimestamp":1741271528,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时32分，Beam Therapeutics Inc.股票出现异动，股价大幅下挫5.09%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.66%。其相关个股中，Plus Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Exicure, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为953.51%、104.36%、48.88%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.，振幅分别为24.20%、13.05%、11.88%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223208a2628fde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223208a2628fde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4588","BK4139","BK4585","BEAM","BK4505","LENZ","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670089","title":"Beam Therapeutics Inc.盘中异动 早盘急速下挫5.18%报23.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516670089?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099972,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分，Beam Therapeutics Inc.股票出现异动，股价大幅跳水5.18%。截至发稿，该股报23.80美元/股，成交量20.2093万股，换手率0.24%，振幅2.47%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225252abe7f683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225252abe7f683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","BK4535","BK4556","BK4139","LENZ","BEAM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516619511","title":"数据：在PEPE、BEAM等代币上损失千万美元的巨鲸转向购买BTC和MKR","url":"https://stock-news.laohu8.com/highlight/detail?id=2516619511","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516619511?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:42","pubTimestamp":1741063374,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"jinse_live","url":"https://x.com/OnchainLens/status/1896779398776512797","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/OnchainLens/status/1896779398776512797","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BEAM","ETH","ETH.USD.HKCC","BK4505","MKR.USD.HKCC","BK4139","BK4535","BTCmain","XBTmain","BK4601","BK4585","BK4556","BTC","BK4588","MKR.USD.CC","BTC.USD.HKCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663938","title":"Beam Therapeutics Inc.盘中异动 下午盘股价大跌5.13%报24.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516663938?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:28","pubTimestamp":1741033681,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时28分，Beam Therapeutics Inc.股票出现波动，股价大幅跳水5.13%。截至发稿，该股报24.99美元/股，成交量81.582万股，换手率0.97%，振幅6.47%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042801abe695f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042801abe695f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4556","BK4588","LENZ","BK4139","BEAM","BK4535","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516786035","title":"某巨鲸以1.17美元均价增持534万枚ONDO，曾投资PEPE及BEAM亏损超1400万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516786035","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516786035?lang=zh_cn&edition=full","pubTime":"2025-03-03 10:58","pubTimestamp":1740970730,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"jinse_live","url":"https://x.com/OnchainLens/status/1896388254917955585","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/OnchainLens/status/1896388254917955585","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BK4535","MKR.USD.HKCC","BK4556","BK4139","BK4585","BK4505","BEAM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516341379","title":"Beam Therapeutics Inc.2024财年实现净利润-3.77亿美元，同比减少183.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516341379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516341379?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:01","pubTimestamp":1740758461,"startTime":"0","endTime":"0","summary":"3月1日，Beam Therapeutics Inc.公布财报，公告显示公司2024财年净利润为-3.77亿美元，同比减少183.46%；其中营业收入为63.52百万美元，同比减少83.20%，每股基本收益为-4.58美元。从资产负债表来看，Beam Therapeutics Inc.总负债3.70亿美元，其中短期债务13.47百万美元，资产负债比为2.99，流动比率为4.83。机构评级：截至2025年3月1日，当前有14家机构对Beam Therapeutics Inc.目标价做出预测，其中目标均价为48.43美元，其中最低目标价为24.00美元，最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000154a258185b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000154a258185b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514186503","title":"Beam Therapeutics Inc.盘中异动 大幅下跌5.06%报28.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514186503?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:57","pubTimestamp":1740592630,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时57分，Beam Therapeutics Inc.股票出现异动，股价急速下挫5.06%。截至发稿，该股报28.33美元/股，成交量52.8583万股，换手率0.63%，振幅5.50%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.43%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270157109893d107&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270157109893d107&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BK4556","BK4588","BK4139","BK4535","BEAM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beamtx.com","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.1384},{"period":"3month","weight":-0.0955},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.5842},{"period":"ytd","weight":-0.0364}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Beam Therapeutics Inc.成立于2017年1月25日，是一家生物技术公司，致力于根据其专有的碱基编辑技术创建一类新型的精密基因药物，其愿景是为患有严重疾病的患者提供终身治疗疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.016429},{"month":2,"riseRate":0.666667,"avgChangeRate":0.107924},{"month":3,"riseRate":0,"avgChangeRate":-0.199132},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.070856},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076367},{"month":6,"riseRate":0.857143,"avgChangeRate":0.13469},{"month":7,"riseRate":0.428571,"avgChangeRate":0.035999},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.02261},{"month":9,"riseRate":0.333333,"avgChangeRate":0.012795},{"month":10,"riseRate":0.5,"avgChangeRate":0.022792},{"month":11,"riseRate":0.833333,"avgChangeRate":0.165588},{"month":12,"riseRate":0.5,"avgChangeRate":0.076029}],"exchange":"NASDAQ","name":"Beam Therapeutics, Inc.","nameEN":"Beam Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Beam Therapeutics, Inc.,BEAM,Beam Therapeutics, Inc.股票,Beam Therapeutics, Inc.股票老虎,Beam Therapeutics, Inc.股票老虎国际,Beam Therapeutics, Inc.行情,Beam Therapeutics, Inc.股票行情,Beam Therapeutics, Inc.股价,Beam Therapeutics, Inc.股市,Beam Therapeutics, Inc.股票价格,Beam Therapeutics, Inc.股票交易,Beam Therapeutics, Inc.股票购买,Beam Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}